Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SPX6900 (SPX) To Rise Higher? Key Harmonic Pattern Signals Potential Upside Move

SPX6900 (SPX) To Rise Higher? Key Harmonic Pattern Signals Potential Upside Move

BitgetBitget2025/06/28 12:32
By:Bitget

Date: Sat, June 28, 2025 | 08:59 AM GMT

The cryptocurrency market is making a steady recovery as geopolitical tensions between Israel and Iran begin to cool down. Ethereum (ETH) has rebounded sharply, climbing from its recent low of $2,113 to approach $2,425. Riding this renewed momentum, memecoins are catching a bid—especially SPX6900 (SPX).

SPX is currently posting impressive daily gains of 6%, extending its weekly rally to over 18%. But more importantly, a key technical pattern is flashing a signal for further upside.

SPX6900 (SPX) To Rise Higher? Key Harmonic Pattern Signals Potential Upside Move image 0 Source: Coinmarketcap

Harmonic Pattern Signals More Upside

On the 4-hour chart, SPX is forming a bullish extension of a Bearish Butterfly harmonic pattern—a setup known for forecasting one last upside leg before a reversal zone. Despite the name, butterfly patterns can provide bullish opportunities until they reach the final D point.

The pattern begins at the local high of $1.7103 (point X), dipping to $0.9236 (point A), forming the XA leg. From there, SPX rebounded to $1.4098 (point B), a 61.8% retracement of XA. The next move down to $1.09 (point C) marked a healthy 64.0% retracement of the AB leg. Now, the CD leg is developing and pointing higher.

SPX6900 (SPX) To Rise Higher? Key Harmonic Pattern Signals Potential Upside Move image 1 SPX6900 (SPX) 4H Chart/Coinsprobe (Source: Tradingview)

According to the harmonic structure, if the CD leg completes successfully, the next target is around $1.92, marked by the 1.272 Fibonacci extension of the XA leg. Beyond that, the 1.618 extension at $2.19 also comes into play—often viewed as a final exhaustion zone for butterfly setups.

What’s Next for SPX?

Currently trading around $1.25, SPX is approaching a critical test of the 100-day moving average at $1.31. A confirmed breakout above this level could open the door to a move toward $1.92, offering nearly 52% upside from current prices. If bullish momentum continues across the broader crypto market, SPX could even overshoot toward the 1.618 extension at $2.19—a 73% potential gain from here.

However, if SPX fails to hold above the $1.09 support zone or gets rejected below the 100 MA, a period of sideways consolidation or a short-term pullback might follow before any sustainable move resumes.

Disclaimer: This article is for informational purposes only and not financial advice. Always conduct your own research before investing in cryptocurrencies.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf

Crossing the break-even line, the growth inflection point has arrived.

智通财经•2026/11/11 03:22

Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot

Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.

智通财经•2026/11/11 03:06

Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality

The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.

智通财经•2026/11/11 02:56
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality